KRAS and neoplasm: These results highlight the potential for either PTEN loss or KRAS activation to promote tumor cell survival in vivo that could increase recurrence risk, and the unique ability of the combined mutations to yield rapid tumor growth that could influence tumor subtypes where these mutations are common.